Extracellular Vesicles: Versatile Nanomediators, Potential Biomarkers and Therapeutic Agents in Atherosclerosis and COVID-19-Related Thrombosis세포외 소포: 죽상경화증 및 COVID-19 관련 혈전증에서 다목적 나노매개체, 잠재적 바이오마커 및 치료제Review Published on 2021-05-312022-09-10 Journal: International Journal of Molecular Sciences [Category] 바이오마커, [키워드] agent atherogenesis Atherosclerosis atherosclerotic Biomarker Biomarkers cardiovascular disease cardiovascular diseases cargo Cell cells Characteristics coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient cytoplasmic proteins DNA Effect endocytosis endothelial EVs Exosomes extracellular vesicle Extracellular vesicles immune cells information mechanism mediators Mesenchymal stromal cells metabolites microRNA Microvesicles mRNA participant pathological condition Pathologies Platelets Potential receptors Signaling stromal cells therapeutic agents therapeutic potential thrombosis thrombotic Thrombotic events transfer variety [DOI] 10.3390/ijms22115967 PMC 바로가기 [Article Type] Review
SARS-CoV-2/COVID-19 pandemic: first wave, impact, response and lessons learnt in a fully integrated Regional Blood and Tissue Bank. A narrative reportSARS-CoV-2/COVID-19 전염병: 완전히 통합된 지역 혈액 및 조직 은행에서 첫 번째 물결, 영향, 대응 및 교훈. 내러티브 보고서Article Published on 2021-03-012022-09-11 Journal: Blood transfusion = Trasfusione del sangue [Category] SARS, 치료기술, [키워드] activity adverse effect Ambiguity Bank being Blood BST Care cells changes in clinical trial clinical trials Combination complexity convalescent plasma COVID-19 COVID-19 pandemic Critical described development diagnoses Donor donors effective element First wave flexibility Health health system International management material measure Mesenchymal stromal cells occurred pandemic Participation Patient patients promote Recognition recommendation Regional Research research and development response risk service Stress stromal cells Support tissue Tissue Bank volatility [DOI] 10.2450/2021.0259-20 PMC 바로가기 [Article Type] Article
Challenges and advances in clinical applications of mesenchymal stromal cells간엽 기질 세포의 임상 응용 분야에서의 도전과 발전Review Published on 2021-02-122022-09-10 Journal: Journal of Hematology & Oncology [Category] Fulltext, MERS, 비임상, [키워드] approach Artificial intelligence (AI) breath challenge Clinical applications clinical trial COVID-19 COVID-19 pandemic criteria disease disease models Diversity Extracellular vesicles Factor heterogeneity highest human disease human diseases identity improvement investigated majority Mesenchymal stem cells Mesenchymal stromal cell Mesenchymal stromal cells modify MSC MSC therapy MSCs outcome overcome pandemic disease Registered stem cells stromal cell stromal cells therapeutic potential [DOI] 10.1186/s13045-021-01037-x PMC 바로가기 [Article Type] Review
Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case seriesCOVID-19로 유발된 중증 ARDS 환자 치료를 위한 주산기 조직 유래 중간엽 줄기세포: 사례 시리즈Clinical Trial Published on 2021-01-292022-08-13 Journal: Stem Cell Research & Therapy [Category] 바이오마커, 임상, 진단, [키워드] acute renal and hepatic failure acute respiratory distress syndrome age Allogeneic allogeneic prenatal Alpha ARDS ARDS patients C-reactive protein C-reactive protein (CRP candidate Cardiac arrest Cardiomyopathy case sery cell infusion cell infusions Cell therapy cells chronic lymphocytic leukemia clinical trial CLL CMP Comorbidities Comorbidity Computed tomography coronavirus disease Coronavirus disease 2019 COVID-19 Critically ill develop diabetes diagnosed died discharged distress Dyspnea eight enrolled fatal complication feasibility finding FIVE hepatic failure High dose hospital human umbilical cord MSCs hypertension Hypoxemia ICU ICUs IFN-γ IL-6 IL-6 level IL-6 levels IL-8 IMPROVE Inflammatory biomarker inflammatory biomarkers infusion intensive care unit intensive care units interferon gamma intravenous infusion Large randomized multicenter clinical trials leukemia Leukocytosis lung lymphocyte Lymphocytes mechanical ventilation men mesenchymal stem cell Mesenchymal stem cells Mesenchymal stromal cells MSC MSCs multi-organ failure multicenter one patient outcome Patient patients perinatal tissue Phase 1 PL-MSCs Placenta placental MSC placental MSCs Pneumonia Potential treatment Radiological parameter Radiological parameters Randomized reduce reduced renal reported required respiratory distress Respiratory distress syndrome Safe Sepsis Serious Adverse Event Serious Adverse Events Serum level serum levels Seven severe hypoxemia Significant reduction significant reductions SpO2 stem cell Stem cell therapy supplementary material survivor Survivors syndrome the cell therapeutic potential TNF-α Tolerability Treatment Tumor tumor necrosis tumor necrosis factor tumor necrosis factor-alpha UC-MSCs umbilical Umbilical cord women [DOI] 10.1186/s13287-021-02165-4 PMC 바로가기 [Article Type] Clinical Trial
Evaluation of the safety and efficacy of using human menstrual blood‐derived mesenchymal stromal cells in treating severe and critically ill COVID‐19 patients: An exploratory clinical trial중증 및 중환자 COVID-19 환자 치료에서 인간 월경혈유래 중간엽 기질 세포의 안전성 및 효능 평가: 탐색적 임상 시험Clinical Trial Published on 2021-01-272022-08-13 Journal: Clinical and Translational Medicine [Category] MERS, 임상, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adverse event adverse events AEs Allogeneic alternative method caused chest imaging clinical trial Concomitant medication concomitant medications control group coronavirus coronavirus disease Coronavirus disease 2019 coronavirus disease 2019 (COVID‐19) COVID‐19 COVID‐19 patients Critical Critically ill died Dyspnea effective Efficacy enrolled experimental group exploratory Frequency groups incidence lack menstrual Mesenchymal stromal cell Mesenchymal stromal cells Mortality MSC MSC therapy MSCs multicenter nonrandomized not differ open‐label Patient patients problems proliferation respiratory Safety safety and efficacy SARS‐CoV‐2 secondary endpoint Secondary endpoints severe acute respiratory syndrome Coronavirus severe and critical patients significantly significantly lower Spread stromal cell stromal cells therapy treat treated Treatment Trial was measured were assessed [DOI] 10.1002/ctm2.297 PMC 바로가기 [Article Type] Clinical Trial
Perinatal Cells: A Promising COVID-19 Therapy?Bioengineering and Biotechnology Published on 2021-01-142022-10-31 Journal: Frontiers in Bioengineering and Biotechnology [Category] COVID-19, [키워드] acute respiratory distress Admission Antiviral ARDS cause caused Cell Characteristics coronavirus-induced disease 2019 COVID-19 COVID-19 pandemic Cytokine storm Disseminated intravascular coagulation drug edema Effect exacerbated response fibrosis health system immune system immunomodulatory Inflammatory intensive care lung tissue Mesenchymal stromal cells opportunistic Infections other organs patients with COVID-19 Perinatal placental expanded provide reduce Respiratory system safety profile Sepsis severe acute respiratory distress syndrome coronavirus-2 stimulate subject susceptibility Symptom syndrome therapy tissue Treatment Vaccines viral infection [DOI] 10.3389/fbioe.2020.619980 PMC 바로가기 [Article Type] Bioengineering and Biotechnology
Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trialCOVID-19(COVID-AT)로 인한 급성 호흡 곤란 증후군 환자에서 동종 간엽 기질 세포의 효능을 평가하기 위한 이중 맹검, 무작위, 대조 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-01-062022-09-10 Journal: Trials [Category] MERS, 바이오마커, 임상, 치료제, [키워드] 1:1 24 hours 7-point ordinal scale acute respiratory distress acute respiratory distress syndrome Administered administration Admission Adult patient Adult patients Adverse Adverse drug reactions AEs age All trial participants all-cause mortality allergy Allogeneic ARDS assessment assigned baseline Biomarker blinded Blinding C-reactive protein carcinoma carcinoma in situ carried cellular chain change childbearing potential Chloroquine Clinical practice clinical status clinical trial coagulation test coagulation tests conducted Control control arm Course COVID COVID-19 CRF criteria CT scan cumulative incidence current Cytokines D-dimer Day death described determined by Diagnosis disease dissemination double-blind drug Duration ECMO Efficacy Efficacy and safety element eligible End endpoints enrolment EudraCT evaluate evaluate the effect event exclusion criteria Extracorporeal extracorporeal membrane oxygenation failure ferritin fibrosis FiO2 form GRADE grade 3 greater Haemodialysis handling hemofiltration history hospital Hospitalization hydroxy ICU ICU admission IMPROVE include inclusion criteria Informed consent intravenous Intravenous administration intravenous dose intubation Invasive mechanical ventilation invasive ventilation investigational medicinal product involved laboratory confirmation laboratory-confirmed SARS-CoV-2 infection lactation LDH less Level Local Lopinavir Lopinavir/ritonavir lung disorder lymphocyte marker Mechanical mechanical ventilation Medicine Medicines Mesenchymal stromal cells moderate to severe Mortality MSC negative pregnancy test neoplasm neutrophil neutrophil counts Non-invasive number objective occur off-label opinion Ordinal Scale organ oropharyngeal swab oropharyngeal swabs Other outcome oxygen oxygen saturation Oxygen therapy PaO2 PaO2/FiO2 ratio parameters participant Patient PCR percentage Placebo polymerase chain reaction Pregnancy primary endpoint product Production profile progression protocol Pulmonary embolism pulmonary fibrosis Pulmonary function tests randomised randomised controlled trial randomization Randomized Randomly Rapid antigen tests reaction receive recruitment Registered Remdesivir report respiratory Respiratory distress syndrome Resuscitation Ritonavir SAEs Sample size SARS-COV-2 infection secondary Secondary endpoints Sequential Organ Failure Assessment Serious Adverse Events SOFA Spain specificity specimen Sponsor Standard of care status stromal cell stromal cells Study protocol subpopulations supplemental oxygen supplementary material syndrome the cell the disease the patient the primary endpoint the WHO time Tocilizumab Tolerability Treatment treatment arm treatment for COVID-19 treatment group Treatment protocol Trial trial participant Trial registration unit website women worldwide pandemic written consent [DOI] 10.1186/s13063-020-04964-1 PMC 바로가기 [Article Type] Letter
Combined Use of Tocilizumab and Mesenchymal Stromal Cells in the Treatment of Severe Covid-19: Case Report중증 코비드-19 치료에 토실리주맙과 중간엽 기질 세포의 병용: 증례 보고Case Reports Published on 2021-01-012022-09-12 Journal: Cell transplantation [Category] 진단, [키워드] acute respiratory syndrome adverse effects Case report Combination Combined coronavirus COVID-19 critical condition decrease Dexamethasone drug event Hospital stay Mesenchymal stromal cells Mortality nasal catheter pandemic Patient prophylactic dose public health report reported respond Safe SARS-CoV-2 specific treatment standard procedure stromal cell Symptoms tested the disease therapy Tocilizumab treated Treatment UC-MSC umbilical Umbilical cord [DOI] 10.1177/09636897211021008 PMC 바로가기 [Article Type] Case Reports
Current Status and Future Prospects of Perinatal Stem Cells주산기 줄기세포 현황 및 향후 전망Review Published on 2020-12-232022-09-10 Journal: Genes [Category] MERS, SARS, 임상, [키워드] Allogeneic amniotic fluid/membrane Birth Blood candidate carried Cell Cell therapy cell type cell types Characteristics chorion circulatory systems clinical settings clinical trial clinical trials contribute Cord blood COVID-19 COVID19 pneumonia current decidua described feature fetus Future gestation growth hematological immunological disorder independent individual intrinsic Mesenchymal stromal cells mother nanomedicine non-hematopoietic cell non-hematopoietic cells organ Other Pathologies Perinatal perinatal tissue perinatal tissues phenotypical Placenta Pneumonia primary source regenerative regenerative medicine status STEM stem cell stem cells stromal cell stromal cells therapeutic therapy these cell These cells tissue tissue engineering tissues treat trials umbilical cord tissue/blood unique [DOI] 10.3390/genes12010006 PMC 바로가기 [Article Type] Review
Mesenchymal stromal cells for sepsis and septic shock: Lessons for treatment of COVID-19패혈증 및 패혈성 쇼크에 대한 중간엽 기질 세포: COVID-19 치료를 위한 교훈Article Published on 2020-12-012022-09-11 Journal: Stem cells translational medicine [Category] SARS, 임상, [키워드] absence acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 ARDS caused cells clinical trials complex coronavirus COVID-19 defined deregulated immune host response Infection lesson life-threatening Mesenchymal stromal cell Mesenchymal stromal cells mesenchymal stromal/stem cells multifactorial organ dysfunction question respiratory respiratory distress Respiratory distress syndrome SARS-CoV-2 Sepsis Septic shock severe acute respiratory syndrome Coronavirus specific treatment stromal cells syndrome tested These cells Treatment Wharton's Jelly [DOI] 10.1002/sctm.20-0239 PMC 바로가기 [Article Type] Article